This is a monoclonal antibody treatment of GlaxoSmithKline and an immunosuppressive drug already authorized in the EU for the treatment of various inflammatory conditions.
Le Monde and Reuters
The European Medicines Agency (AEM) approved Thursday, December 16, two new treatments against CVIV-19: Xevudy (Sotrovimab), monoclonal antibody treatment developed by the British GSK laboratory, in partnership with the biotech American vir biotechnology, as well as Kineret, an immunosuppressive drug already authorized in the EU for the treatment of various inflammatory conditions.
The GSK treatment ” is intended for the treatment of COVID-19 in adults and adolescents (from 12 years old and weighing at least 40 kilograms) that do not need Additional oxygen and an increased risk of seriousness of the disease, “said EMA in a statement. According to the agency, in view of laboratory tests, Xevudy should be effective against different variants of the coronavirus, including Omicron.
Xevudy is the third treatment of COCI-19 monoclonal antibodies validated in the European Union, after the green light granted last month to Regkirona (Regdanvimab), Celletrion, and Ronapreve (Casirivimab and Imdevimab) , from Rock and Regeneron. The monoclonal antibodies are proteins designed to attach to a specific target, in this case the advanced SARS-COV-2 protein (the virus that causes CVIV-19), that the virus uses to enter human cells.
Processing used for inflammatory affections
In a second press release, the AEM explains that The use of Kineret , marketed by the Swedish laboratory Orphan Biovitruma has been “extended to the treatment of CVIV-19 in adult patients (… ) Needing an oxygen supplement (…) and which may develop severe respiratory failure “.
The AEM recalls that this medicine “is currently authorized in the EU for the treatment of various inflammatory conditions. In patients with COVID-19, the drug is considered to reduce the inflammation associated with CVIV-19 and Thus decreasing the damage to the lower respiratory tract, thus preventing the development of severe respiratory failure “.